Loading...
•
Sep 30, 2020
Aytu BioScience Q1 2021 Earnings Report
Aytu BioScience's Q1 2021 financial results were announced, featuring a significant revenue increase and a reduced EBITDA loss.
Key Takeaways
Aytu BioScience reported a substantial increase in net revenue for Q1 2021, reaching $13.5 million, an 839% increase year-over-year. The company reduced its adjusted EBITDA loss to $1.3 million and holds $38.2 million in cash and cash equivalents.
Net revenue increased by 839% year-over-year to $13.5 million.
Consumer Health net revenue reached an all-time high of $7.8 million.
Rx net revenue was $5.8 million, compared to $1.4 million in Q1 last year.
Net loss was $4.3 million, and adjusted EBITDA loss was $1.3 million.
Forward Guidance
The company has strong momentum to maximize shareholder value moving ahead in fiscal 2021 and beyond.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...